Cocrystal Pharma Announces Appointment of Nobel Laureate and Scientific Advisor, Roger D. Kornberg, Ph.D., to Board of Direct...
April 20 2020 - 8:05AM
Cocrystal Pharma, Inc. (NASDAQ: COCP), (“Cocrystal” or
the “Company”), a clinical stage biotechnology company
discovering and developing novel antiviral therapeutics,
announced today the appointment of Dr. Roger Kornberg to its Board
of Directors. Dr. Kornberg has served as the Company’s Chief
Scientist and Chairman of our Scientific Advisory Board.
Dr. Kornberg is a member of the U.S. National
Academy of Sciences and the Winzer Professor of Medicine in the
Department of Structural Biology at Stanford University. He has
been a member of the faculty of Stanford University since 1978.
“Dr. Kornberg has been an integral part of
Cocrystal for many years. His leadership and expertise while
serving as our Chief Scientist and Chairman of our Scientific
Advisory Board have been pivotal as we’ve advanced our pipeline of
first- and best-in-class antiviral drugs. We are incredibly pleased
to welcome him to our Board of Directors and to continue leveraging
his knowledge and experience to identify and develop new antiviral
compounds,” commented Dr. Gary Wilcox, Chairman and Chief Executive
Officer of Cocrystal.
In 2006, Dr. Kornberg was awarded the Nobel
Prize in Chemistry in recognition for his studies of the molecular
basis of Eukaryotic Transcription, the process by which DNA is
copied to RNA. Dr. Kornberg is also the recipient of several
awards, including the 2001 Welch Prize, the highest award granted
in the field of chemistry in the United States, and the 2002
Leopald Mayer Prize, the highest award granted in the field of
biomedical sciences from the French Academy of Sciences.
Dr. Kornberg commented, “I am pleased to be
strengthening my relationship with Cocrystal by joining the
Company’s Board of Directors at this exciting time. I strongly
believe in the potential of the proprietary drug discovery platform
technology and its utility in influenza, hepatitis C, COVID-19, and
gastroenteritis. I continue to be encouraged by the positive data
generated to date across this rich pipeline of development
programs.” About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical stage
biotechnology company discovering and developing novel antiviral
therapeutics that target the replication process of influenza
viruses, hepatitis C viruses, coronaviruses, and noroviruses.
Cocrystal employs unique structure-based technologies and Nobel
Prize winning expertise to create first- and best-in-class
antiviral drugs. For further information about Cocrystal, please
visit www.cocrystalpharma.com.
Investor and Media Contact:JTC
Team, LLC(833) 475-8247COCP@jtcir.com
###
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cocrystal Pharma (NASDAQ:COCP)
Historical Stock Chart
From Apr 2023 to Apr 2024